The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for preventing disease in this at-risk population. The conjugate vaccine induces a T-cell dependent response, which distinguishes it from the polysaccharide vaccine and could provide the longer-term protection necessary to have a significant impact in this population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964835 | PMC |
| http://dx.doi.org/10.1080/21645515.2016.1147638 | DOI Listing |
Publication Analysis
Top Keywords
conjugate vaccine
12
pneumococcal conjugate
8
vaccine
4
vaccine adults
4
adults let's
4
let's recommendation
4
recommendation 13-valent
4
13-valent pneumococcal
4
vaccine pcv13
4
pcv13 adults
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!